QQ客服 官方微博 反馈留言

	In silico drug design of inhibitor of nuclear factor kappa B kinase subunit beta inhibitors from 2-acylamino-3-aminothienopyridines based on quantitative structure-activity relationships and molecular docking
	Wang, Jiao-Long[1]; Li, Liang[2]; Hu, Mei-Bian[1]; Wu, Bo[1]; Fan, Wen-Xiang[1]; Peng, Wei[1]; Wei, Da-Neng[1]; Wu, Chun-Jie[1]
	2019
卷号	78页码:297-305
URL标识	查看原文
WOS记录号	WOS:000459524900030
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4336546
专题	成都中医药大学
作者单位	1.[1]Chengdu Univ Tradit Chinese Med, Sch Pharm, Chengdu 611137, Sichuan, Peoples R China 2.[2]Chengdu Univ Tradit Chinese Med, Sch Clin Med, Chengdu 611137, Sichuan, Peoples R China
推荐引用方式 GB/T 7714	Wang, Jiao-Long[1],Li, Liang[2],Hu, Mei-Bian[1],et al. In silico drug design of inhibitor of nuclear factor kappa B kinase subunit beta inhibitors from 2-acylamino-3-aminothienopyridines based on quantitative structure-activity relationships and molecular docking[J],2019,78:297-305.
APA	Wang, Jiao-Long[1].,Li, Liang[2].,Hu, Mei-Bian[1].,Wu, Bo[1].,Fan, Wen-Xiang[1].,...&Wu, Chun-Jie[1].(2019).In silico drug design of inhibitor of nuclear factor kappa B kinase subunit beta inhibitors from 2-acylamino-3-aminothienopyridines based on quantitative structure-activity relationships and molecular docking.,78,297-305.
MLA	Wang, Jiao-Long[1],et al."In silico drug design of inhibitor of nuclear factor kappa B kinase subunit beta inhibitors from 2-acylamino-3-aminothienopyridines based on quantitative structure-activity relationships and molecular docking".78(2019):297-305.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。